FI121176B - Lymfosyyttien sitoutumiseen vaikuttava ihmisen endoteelisolun molekyyli - Google Patents

Lymfosyyttien sitoutumiseen vaikuttava ihmisen endoteelisolun molekyyli Download PDF

Info

Publication number
FI121176B
FI121176B FI20095269A FI20095269A FI121176B FI 121176 B FI121176 B FI 121176B FI 20095269 A FI20095269 A FI 20095269A FI 20095269 A FI20095269 A FI 20095269A FI 121176 B FI121176 B FI 121176B
Authority
FI
Finland
Prior art keywords
vap
antibody
binding
lymphocytes
cells
Prior art date
Application number
FI20095269A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI20095269A (fi
Inventor
Sirpa Jalkanen
Marko Salmi
Original Assignee
Biotie Therapies Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25404388&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI121176(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biotie Therapies Corp filed Critical Biotie Therapies Corp
Publication of FI20095269A publication Critical patent/FI20095269A/fi
Application granted granted Critical
Publication of FI121176B publication Critical patent/FI121176B/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Toxicology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
FI20095269A 1992-06-09 2009-03-16 Lymfosyyttien sitoutumiseen vaikuttava ihmisen endoteelisolun molekyyli FI121176B (fi)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US89535492A 1992-06-09 1992-06-09
US89535492 1992-06-09
FI9300250 1993-06-09
PCT/FI1993/000250 WO1993025582A1 (en) 1992-06-09 1993-06-09 A novel endothelial cell molecule mediating lymphocyte binding in man

Publications (2)

Publication Number Publication Date
FI20095269A FI20095269A (fi) 2009-03-16
FI121176B true FI121176B (fi) 2010-08-13

Family

ID=25404388

Family Applications (1)

Application Number Title Priority Date Filing Date
FI20095269A FI121176B (fi) 1992-06-09 2009-03-16 Lymfosyyttien sitoutumiseen vaikuttava ihmisen endoteelisolun molekyyli

Country Status (14)

Country Link
EP (1) EP0656906B1 (es)
JP (2) JP3431922B2 (es)
KR (1) KR100268772B1 (es)
AT (1) ATE184315T1 (es)
AU (1) AU671837B2 (es)
CA (1) CA2137551C (es)
DE (1) DE69326347T2 (es)
DK (1) DK0656906T3 (es)
ES (1) ES2135480T3 (es)
FI (1) FI121176B (es)
GR (1) GR3031255T3 (es)
HU (1) HU217175B (es)
NZ (2) NZ253151A (es)
WO (1) WO1993025582A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100533911B1 (ko) * 1997-05-23 2005-12-06 바이오티에 세라피스 코포레이션 아민 산화효소의 활성을 갖는 혈관 점착 단백질-1
FI20020807A0 (fi) * 2002-04-29 2002-04-29 Biotie Therapies Oyj Uusia humanisoituja anti-VAP-1 monoklonaalisia vasta-aineita
FI20061156A0 (fi) 2006-12-27 2006-12-27 Elina Kivi Uusia peptidejä
FI20075278A0 (fi) * 2007-04-20 2007-04-20 Biotie Therapies Corp Uudet täysin ihmisperäiset anti-VAP-1 monoklonaaliset vasta-aineet

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0703989B1 (en) * 1993-06-18 1997-11-05 Oy Biotie Therapies COMPOSITIONS AND DIAGNOSTIC METHODS USING MONOCLONAL ANTIBODIES AGAINST CD44v6

Also Published As

Publication number Publication date
JP3431922B2 (ja) 2003-07-28
EP0656906B1 (en) 1999-09-08
AU4328193A (en) 1994-01-04
CA2137551C (en) 2002-03-26
WO1993025582A1 (en) 1993-12-23
NZ299958A (en) 2000-07-28
JP2003180346A (ja) 2003-07-02
DK0656906T3 (da) 1999-12-20
ATE184315T1 (de) 1999-09-15
DE69326347D1 (de) 1999-10-14
GR3031255T3 (en) 1999-12-31
CA2137551A1 (en) 1993-12-23
HUT75824A (en) 1997-05-28
HU217175B (hu) 1999-12-28
AU671837B2 (en) 1996-09-12
NZ253151A (en) 1997-03-24
KR950701938A (ko) 1995-05-17
JPH07507557A (ja) 1995-08-24
ES2135480T3 (es) 1999-11-01
EP0656906A1 (en) 1995-06-14
FI20095269A (fi) 2009-03-16
JP3500384B2 (ja) 2004-02-23
HU9403516D0 (en) 1995-02-28
DE69326347T2 (de) 2000-02-24
KR100268772B1 (ko) 2000-10-16

Similar Documents

Publication Publication Date Title
Salmi et al. A 90-kilodalton endothelial cell molecule mediating lymphocyte binding in humans
Rosenberg et al. Mac-2-binding glycoproteins. Putative ligands for a cytosolic beta-galactoside lectin.
Wellicome et al. Detection of a circulating form of vascular cell adhesion molecule-1: raised levels in rheumatoid arthritis and systemic lupus erythematosus
Fearns et al. Murine CD14 gene expression in vivo: extramyeloid synthesis and regulation by lipopolysaccharide.
Schuppan et al. Undulin, an extracellular matrix glycoprotein associated with collagen fibrils.
Gruschwitz et al. Correlation of soluble adhesion molecules in the peripheral blood of scleroderma patients with their in situ expression and with disease activity
Orikasa et al. Massive proteinuria induced in rats by a single intravenous injection of a monoclonal antibody.
JP3353209B2 (ja) αｖβ３インテグリンに対する抗体
FI102181B (fi) Menetelmä ICAM-1 (solujen välisen kiinnikemolekyylin) saamiseksi oleel lisesti puhtaassa muodossa
KR900006338B1 (ko) 인체 비소형세포 폐암 및 기타 인체암 치료용 모노클로날 항체 및 항원
Cotmore et al. Purification of Thy‐1‐related glycoproteins from human brain and fibroblasts: comparisons between these molecules and murine glycoproteins carrying Thy‐1.1 and Thy‐1.2 antigens
Katayama et al. A monoclonal antibody-based enzyme immunoassay for human GMP-140/P-selectin
Hosein et al. Monocyte receptors for fibronectin characterized by a monoclonal antibody that interferes with receptor activity.
FI121176B (fi) Lymfosyyttien sitoutumiseen vaikuttava ihmisen endoteelisolun molekyyli
WO1997012913A1 (en) Tumor derived carbohydrate binding protein
US7128905B2 (en) Method of treating graft versus host disease by administration of a Fas antagonist
Burgeson Type VII collagen
BG65579B1 (bg) Състав за лечение на възпалително нарушение
US5580780A (en) Vascular adhesion protein-(VAP-1) and VAP-1-specific antibodies
De Eguileor et al. Lipopolysaccharide-dependent induction of leech leukocytes that cross-react with vertebrate cellular differentiation markers
Uscanga et al. Sequential connective matrix changes in experimental acute pancreatitis. An immunohistochemical and biochemical assessment in the rat
BG63489B1 (bg) Метод за инхибиране активацията на cd долу 40 лиганд на гладкомускулни клетки
Lundberg et al. Changes in cartilage proteoglycan aggrecan after intra-articular injection of interleukin-1 in rabbits: studies of synovial fluid and articular cartilage.
Parks et al. Identification and characterization of an endothelial, cell-specific antigen with a monoclonal antibody
Kitabatake et al. Immunohistochemical demonstration of proteoglycans in the skin of patients with systemic sclerosis

Legal Events

Date Code Title Description
FG Patent granted

Ref document number: 121176

Country of ref document: FI

MA Patent expired